Last reviewed · How we verify
CT-2106
CT-2106 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.
CT-2106 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Relapsed or refractory acute myeloid leukemia.
At a glance
| Generic name | CT-2106 |
|---|---|
| Sponsor | CTI BioPharma |
| Drug class | PI3K inhibitor |
| Target | PI3K delta and PI3K gamma |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting these enzymes, CT-2106 disrupts the PI3K/AKT signaling pathway, which is involved in the proliferation and survival of cancer cells. This leads to the induction of apoptosis and inhibition of tumor growth.
Approved indications
- Relapsed or refractory acute myeloid leukemia
Common side effects
- Cytopenias
- Infections
- Fatigue
Key clinical trials
- Polyglutamate Camptothecin in Treating Patients With Advanced Cancer (PHASE1)
- Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer (PHASE1, PHASE2)
- CT-2106 for the Second Line Treatment of Ovarian Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CT-2106 CI brief — competitive landscape report
- CT-2106 updates RSS · CI watch RSS
- CTI BioPharma portfolio CI